You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 22, 2024

MIFEPRISTONE Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


When do Mifepristone patents expire, and when can generic versions of Mifepristone launch?

Mifepristone is a drug marketed by Genbiopro and Teva Pharms Usa Inc and is included in two NDAs.

The generic ingredient in MIFEPRISTONE is mifepristone. There are six drug master file entries for this compound. Three suppliers are listed for this compound. Additional details are available on the mifepristone profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Mifepristone

A generic version of MIFEPRISTONE was approved as mifepristone by GENBIOPRO on April 11th, 2019.

  Sign Up

AI Research Assistant
Questions you can ask:
  • What is the 5 year forecast for MIFEPRISTONE?
  • What are the global sales for MIFEPRISTONE?
  • What is Average Wholesale Price for MIFEPRISTONE?
Drug patent expirations by year for MIFEPRISTONE
Recent Clinical Trials for MIFEPRISTONE

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Memorial Sloan Kettering Cancer CenterPhase 2
Breast Cancer Research FoundationPhase 2
Astellas Pharma US, Inc.Phase 2

See all MIFEPRISTONE clinical trials

Pharmacology for MIFEPRISTONE
Paragraph IV (Patent) Challenges for MIFEPRISTONE
Tradename Dosage Ingredient Strength NDA ANDAs Submitted Submissiondate
KORLYM Tablets mifepristone 300 mg 202107 1 2017-12-15

US Patents and Regulatory Information for MIFEPRISTONE

MIFEPRISTONE is protected by zero US patents and one FDA Regulatory Exclusivity.

FDA Regulatory Exclusivity protecting MIFEPRISTONE

PATENT CHALLENGE
Exclusivity Expiration: ⤷  Sign Up

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Genbiopro MIFEPRISTONE mifepristone TABLET;ORAL 091178-001 Apr 11, 2019 AB RX No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Teva Pharms Usa Inc MIFEPRISTONE mifepristone TABLET;ORAL 211436-001 Aug 3, 2020 AB RX No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.